* New Paper * – Antisense Oligonucleotide-Assisted RCA

This publication by Amal Mathai was recognized as HIGHLY IMPACTFUL by the reviewers

Sensitive detection of viral RNA is critical for reliable diagnostics, but extensive RNA secondary and tertiary structures often block access to target sites. Rolling circle amplification (RCA) is a promising isothermal strategy that can be primed directly by RNA, but its efficiency is often limited by these structural barriers.

In this work, we present antisense oligonucleotide-assisted RCA (ASO-RCA), a general method that uses short upstream ASOs to remodel RNA structure and expose DNAzyme-generated priming sites. Across five DNAzyme–circular DNA template systems targeting the SARS-CoV-2 genome, ASOs improved template hybridization and RCA output by up to 70-fold. This effect was robust across both linear and quasi-exponential RCA formats and remained effective even in 50% pooled saliva. Clinical testing further showed that ASO-RCA enhanced diagnostic performance, achieving 100% sensitivity and up to 97.5–100% accuracy.

Overall, ASO-DNAzyme-RCA offers a simple, robust, and clinically relevant approach for overcoming RNA structure barriers, enabling more sensitive nucleic acid detection in viral diagnostics.

Check out the full paper HERE.

* New Paper * – Fighting Mutations with Mutations

An on-going challenge with COVID-19, which has huge implications for future pandemics, is the rapid emergence of viral variants that makes diagnostic tools less accurate, calling for rapid identifications of recognition elements for detecting new variants caused by mutations.

We hypothesize that we can fight mutations of the viruses with mutations of existing recognition elements. We demonstrate this concept via rapidly evolving an existing DNA aptamer originally selected with the spike protein (S-protein) of wildtype SARS-CoV-2 for enhanced recognition of the same protein of the Omicron variants.

The new aptamer has acquired 22 mutations within its 40-nucleotide core sequence and improved its binding affinity for the S-proteins of diverse Omicron subvariants by > 100-fold compared to its parental aptamer.

The aptamer was implemented into an enzyme-linked aptamer binding assay (ELABA), which was applied for detecting Omicron variants in the saliva of infected patients. The assay produced a sensitivity of 86.5% and a specificity of 100%, which was established with 83 clinical samples

Check out the full paper HERE.

* New Paper * – Improving Accessibility to the Substrate for RNA-cleaving DNAzymes

Functional nucleic acid-based diagnostics and therapeutics targeting viral genomic RNA must be able to overcome extensive RNA secondary and tertiary structures in order to be effective. This paper demonstrates a new method to improve the accessibility of  RNA-cleaving DNAzymes (10-23) to relatively inaccessible target sites within large, structured RNA molecules from SARS-CoV-2, using antisense DNA oligonucleotides (ASOs) that flank the DNAzyme target site.

We show that this method can be used to improve the accessibility and activity of 10-23 to previously inaccessible target sites by as much as 2000-fold. We also use an ASO screening approach to demonstrate that structured regions within large RNA molecules typically exist near the target site, rather than more distal regions.

Overall this method is a cheap, fast and effective way to improve DNAzyme accessibility to inaccessible target sites within any large RNA molecule.

Check out the full paper HERE.

Aptamers for protection against viral infections

The Li Lab, in collaboration with the Miller Lab, has made progress with using aptamers as therapeutics to prevent infections like COVID-19.

A high binding affinity COVID-19 (C19HBA) aptamer was compared to commercial monoclonal antibodies in a pre-clinical study. Results show that testing has been successful in protected the mouse model used in the pre-clinical study from infection as effectively as commercial monoclonal antibodies.

For the story published by McMaster University, click HERE.

The aptamer research described above is partially funded by Zentek Ltd., a technology development and commercialization company. We’re thankful for the collaboration with both the Miller Lab and Zentek Ltd.

For a news release by Zentek Ltd. on initial testing, click HERE.

For a news release by Zentek Ltd. on the aptamer technology platform, click HERE.

For a news release by Zentek Ltd. on the results of the pre-clinical study, click HERE.

New DNAzyme that requires an organic solvent!

Read about our latest RNA-cleaving DNAzyme, one that requires an organic solvent to function!  

Given that many organic molecules are widely used as solvents in synthetic and analytical chemistry, we were motivated to derive a functional DNAzyme in these conditions. While several DNAzymes in literature have been reported to work under organic conditions, no prior study has ever selected for DNAzymes that strictly require an organic solvent to function.  

In this study, using a positive selection in dimethyl sulfoxide (DMSO) and a negative selection in an aqueous solution, we isolated an RNA-cleaving DNAzyme that strictly requires DMSO for its catalytic activity. A minimized, more efficient version of the DNAzyme was then generated, and applied in a proof-of-concept aptazyme system for sensing applications.  

Overall, we continue to be fascinated by the amazing capabilities of in vitro selection and catalytic DNA! Check out the full paper HERE.

Fluorogenic DNAzyme for F. nucleatum detection

Check out our latest DNAzyme, DT4, a trans-acting DNAzyme that can be activated by a thermally stable protein target which is unique to Fusobacterium nucleatum subspecies.

Our interest in detecting this human pathogenic bacterium resides with the fact that F. nucleatum is associated with many poor health conditions, such as gum disease, adverse pregnancy outcomes, and colorectal cancer.

Our efforts in demonstrating that DT4 can function as a fluorescent sensor in both human saliva and stool samples provides the opportunity to develop diagnostic platforms for F. nucleatum since thermally stable targets overcome the nuclease activity in biological samples.

Click HERE for the full paper.

On the Cover

A research article first published in February 2023 on the characterization of diverse DNA aptamers for recognition of COVID-19 has been featured on the cover of the most recent issue (issue #5) of the journal Analysis & Sensing.

We’re all very excited and overjoyed with the recognition of all the hard work that’s being done here in the lab.

For the full article, check out the following link:

Comparative Characterization of Diverse DNA Aptamers for Recognition of Spike Proteins of Multiple SARS-CoV-2 Variants

For more papers, see the Publications page of the website.